Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells. The drugmaker has teamed up with ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

A global trade war, sparked by U.S. President Donald Trump, has intensified as he ramped up levies on China while reversing sweeping tariffs on most trading partners, stoking fears of a recession ...

Daiichi Sankyo Co. said on Friday it submitted its mRNA-based COVID-19 vaccine for regulatory approval in Japan. Approval would give Japan a home-grown mRNA vaccine of the type that have made up ...

and Esperion had been looking at the CLEAR results to accelerate take-up. Arguably just as important was the expected cash injection from Daiichi Sankyo, given that Esperion ended 2022 with around ...

Now we would like to begin Daiichi Sankyo's Financial Results Conference ... to the parent company rose by JPY95.0 billion or up 47.3 % to JPY295.8 billion. The exchange rate for the dollar ...

Investing.com -- Daiichi Sankyo Co., Ltd. (TSE:4568) shares surged 6.2% after the pharmaceutical company announced robust fourth-quarter earnings that surpassed expectations, coupled with a ...